The Anti-Aging Arms Race Just Got REAL

Buckle up, because Silicon Valley’s war on aging just leveled up HARD. NewLimit – the biotech brainchild of Coinbase CEO Brian Armstrong – just landed a $130 million Series B to turn back your biological clock at the cellular level.

“We’re not just slowing aging – we’re reversing it at the epigenetic level. Our reprogrammed liver cells behave like they’re decades younger.”

Blake Bryers, NewLimit Co-Founder

💰 The Heavy Hitters Betting on Immortality

• Kleiner Perkins leading the charge (they know a thing or two about backing winners)
• All-star roster including Nat Friedman, Khosla Ventures, and Founders Fund
• Total funding now at $170M+ after their $40M Series A

🧬 The Science That’ll Blow Your Mind

NewLimit’s secret sauce? Epigenetic reprogramming that makes old cells act young again. Their lab results show:

• 3 prototype medicines already working on liver cells
• Reprogrammed cells process fat/alcohol like young healthy ones
• AI-driven “lab in a loop” accelerating discovery exponentially

⚡ Why This Changes EVERYTHING

While human trials are still a few years out, the implications are staggering:

• This isn’t about living longer – it’s about staying healthy longer
• Their AI model tests thousands of drug candidates virtually before lab testing
• Every experiment makes their AI smarter in a self-reinforcing cycle

“The longevity space is heating up like crypto in 2020. With Retro Biosciences and Altos Labs in the game, we’re about to see some SERIOUS breakthroughs.”

Biotech Industry Insider

🔮 The Future is Coming FAST

The longevity gold rush is ON:

• Retro Biosciences raising $1B after $180M from Sam Altman
• Altos Labs launched with $3B from Jeff Bezos
• NewLimit’s tech could be the most scalable approach yet

Bottom line: The first company to crack biological age reversal will create the most valuable medical breakthrough in history. And NewLimit just got $130M closer to making it reality.